ArticleExpert review of ophthalmology2012
Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.
Article in Expert review of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Review: Neuroprotective Nanocarriers in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Navigating the Gene Co-Expression Network and Drug Repurposing Opportunities for Brain Disorders Associated with Neurocognitive Impairment.Brain sciences · 2023Article
- Neuroprotection in glaucoma.Indian journal of ophthalmology · 2022Review
- From the PnTx2-6 Toxin to the PnPP-19 Engineered Peptide: Therapeutic Potential in Erectile Dysfunction, Nociception, and Glaucoma.Frontiers in molecular biosciences · 2022Review
- Oral Scutellarin Treatment Ameliorates Retinal Thinning and Visual Deficits in Experimental Glaucoma.Frontiers in medicine · 2021Article
- Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma.Scientific reports · 2020Article
- Development and characterization of a new rat ocular hypertension model induced by intracameral injection of conjunctival fibroblasts.Scientific reports · 2019Article
- Oxidative Stress-Related Molecular Biomarker Candidates for Glaucoma.Investigative ophthalmology & visual science · 2017Article
- Targeting neuronal gap junctions in mouse retina offers neuroprotection in glaucoma.The Journal of clinical investigation · 2017Article
- Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.Drugs & aging · 2015Review
- Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure.Translational vision science & technology · 2015Article
- Activation of muscarinic receptors protects against retinal neurons damage and optic nerve degeneration in vitro and in vivo models.CNS neuroscience & therapeutics · 2014Article
- Proximal inhibition of p38 MAPK stress signaling prevents distal axonopathy.Neurobiology of disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Primary open-angle glaucoma, a long-term degenerative ocular neuropathy, remains a significant cause of vision impairment worldwide. While many risk factors have been correlated with increased risk for primary open-angle glaucoma, intraocular pressure (IOP) remains the only modifiable risk factor and primary therapeutic target. Pharmacologic therapies are administered topically; these include α(2)-agonists, β-antagonists, prostaglandin analogs and carbonic anhydrase inhibitors. Some of these topical medications exhibit secondary neuroprotective effects independent of their effect on IOP. This review covers the possible mechanisms of neuroprotection stimulated by drugs currently marketed for the lowering of IOP, based on known literature. While the neuroprotective properties of many glaucoma pharmaceuticals are promising from an experimental standpoint, key challenges for the development of new clinical practices include unknown systemic side effects, limited methods of drug delivery to the retina and optic nerve, and development of extended-release formulations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.